Clinical Trial Update: A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma [Phase 3]

View source ↗

Summary

Clinical trial update for Nofazinlimab (CS1003) in advanced hepatocellular carcinoma; the Phase 3 study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Nofazinlimab (CS1003) (nofazinlimab)

Snippet

Sponsor: CStone Pharmaceuticals | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING